

### **Quotation Advert**

| PROVINCE OF KWAZULU-NATAL                |  |          |
|--|--|----------|
| Opening Date:                            | 2020-07-08   |          |
| Closing Date:                            | 2020-07-16   | ii a     |
| Closing Time:                            | 11:00  |          |
| INSTITUTION DETAILS                      |  |          |
| Institution Name:                        | Edendale hospital                                  | $\nabla$ |
| Province:                                | KwaZulu-Natal                                      |          |
| Department or Entity:                    | Department of Health                               |          |
| Division or section:                     | Central Supply Chain Management                    |          |
| Place where goods / services is required | Edendale Hospital SCM Main stores                  | !        |
| Date Submitted                           | 2020-07-08   | 11:0     |
| ITEM CATEGORY AND DETAILS                |  |          |
| Quotation Number:                        | ZNQ:<br>1587/19-20                                 |          |
| Item Category:                           | Services   | $\vee$   |
| Item Description:                        | Paediatric patient record that has 144 (11) Pages  | :        |
|  | As per specification attached                      |          |
|  | NB: The pages are printed in a back to back format | ŧ        |
|  |  |          |
|  |  | )<br>    |
|  |  | :        |
|  |  |          |
| Quantity (if supplies)                   | 24 000 units                                       | i        |
| COMPULSORY BRIEFING SESSION /            | SITE VISIT   |          |
| Select Type:                             | Not Applicable                                     | $\vee$   |
| Date:                                    |  | 100      |
| Time:                                    |  | i        |
| Venue:                                   |  | :        |
|  |  |          |
| QUOTES CAN BE COLLECTED FROM:            | Print from the intranet                            |          |
| QUOTES SHOULD BE DELIVERED TO:           | Blue tender box at Edendale hospital main gate     |          |
|  |  | •        |
| ENQUIRIES REGARDING THE ADVE             |  |          |
| Name:                                    | Sizwe  | . !      |
| Email:                                   | NO EMAILED QUOTATION WILL BE CONSIDERED            | !        |
| Contact Number:                          | 033 395 4570                                       | į        |
| Finance Manager Name:                    | My Dan Thangalan                                   | :        |
| Finance Manager Signature:               | (Krele   | _        |

No late quotes will be considered

| Submit   🔁 Save   Save As | 🔞 Close 🔄 Print Preview |
|---------------------------|-------------------------|
|---------------------------|-------------------------|

Print this page

#### Note:

- 1. The completed Quotation Advert must be printed and signed by the Finance manager.
- 2. A signed copy of the Quotation Advert must be scanned and emailed to web administration: webmaster@kznhealth.gov.za for uploading to the department website.
- 3. N.B if the scanned copy emailed to web Administration is not a signed copy (by the finance manager), the advert/award WiLL NOT be uploaded.

Site Updated:06 July, 2020, 02:33 pm

The materials on this website may be copied for non-commercial use as long as our copyright notice and website address are included.

Copyright © KwaZulu-Natal Department of Health, 2000

Contact the Web Administrator

STANDARD QUOTE DOCUMENTATION SUPPLY CHAIN MANAGEMENT OVER R30 000.00 YOU ARE HEREBY INVITED TO QUOTE FOR REQUIREMENTS AT Edendale Hospital DATE ADVERTISED 08-07-2020 CLOSING DATE: 16-07-2020 CLOSING TIME: 11:00 E-MAIL ADDRESS: sizwe.ngcongo@kznhealth.gov.za FACSIMILE NUMBER: 0333954028 PHYSICAL ADDRESS: lot 89 Selby Msimango, road ,Plessislaer ,Pietermaritzburg,3201 ZNQ NUMBER: 1587/19-21 DESCRIPTION: Paediatric patient record that has 11 (Eleven) pages CONTRACT PERIOD ONCE OFF **VALIDITY PERIOD 60 Days** SARS PIN..... (if applicable) CENTRAL SUPPLIER DATABASE REGISTRATION (CSD) NO. UNIQUE REGISTRATION REFERENCE DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS) Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration. The quote box is open from 08:00 to 15:30. ALL QUOTES MUST BE SUBMITTED ON THE OFFICIAL FORMS - (NOT TO BE RE-TYPED) THIS QUOTE IS SUBJECT TO THE PREFERENTIAL PROCUREMENT POLICY FRAMEWORK ACT AND THE PREFERENTIAL PROCUREMENT REGULATIONS, 2011, THE GENERAL CONDITIONS OF CONTRACT (GCC) AND, IF APPLICABLE, ANY OTHER SPECIAL CONDITIONS OF CONTRACT. THE FOLLOWING PARTICULARS MUST BE FURNISHED (FAILURE TO DO SO WILL RESULT IN YOUR QUOTE BEING DISQUALIFIED) NAME OF BIDDER POSTAL ADDRESS STREET ADDRESS TELEPHONE NUMBER CODE......NUMBER...... FACSIMILE NUMBER CODE .......NUMBER......NUMBER..... CELLPHONE NUMBER E-MAIL ADDRESS \_\_\_\_\_ VAT REGISTRATION NUMBER (If VAT vendor) YES NO HAS A B-BBEE STATUS LEVEL VERIFICATION CERTIFICATE BEEN SUBMITTED? (SBD 6.1)

[A B-BBEE STATUS LEVEL VERIFICATION CERTIFICATE/SWORN AFFIDAVIT (FOR EMES& QSES) MUST BE SUBMITTED IN ORDER TO QUALIFY FOR PREFERENCE POINTS FOR B-BBEE]

| OFFICIAL PI  | RICE PAGE I  | FOR QUOTATIONS                                    |                  |               | ZNQ NUMBE             | <sub>3:</sub> 1587/19-20 |   |    |
|--------------|--------------|---|------------------|---------------|-----------------------|--------------------------|---|----|
| DESCRIPTION  | N: Paed      | iatric patient recor                              | d that has       | : 11 (Ele     | ven) page             | es .                     |   |    |
| SIGNATURE    | OF BIDDER    | I hereby agree to all terms and                   | *********        |               |                       |                          |   |    |
| CAPACITY U   | JNDER WHIC   | CH THIS QUOTE IS SIGNED                           |                  | •••••         |                       |                          |   |    |
| Item No      | Quantity     | Description                                       |                  |               | Brand & model         | Country of manufacture   | Price<br>R                              | Гс |
| 1            | 24 000 units | Paediatric patient record the                     | nat has 11 (Elev | ven) pages    |                       |                          |   |    |
|              |              |   |                  | <del></del>   |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
| -            |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              |   |                  |               |                       |                          |   |    |
|              |              | ,   |                  |               |                       |                          |   |    |
| V            |              |   |                  |               |                       | -                        |   |    |
|              |              |   |                  |               |                       |                          | *************************************** |    |
|              |              | 15% (Only if VAT Vendor) RICE (VALIDITY PERIOD 60 | Davs)            |               |                       |                          |   |    |
|              |              | With The Specification?                           |                  | o Article Con | form To The S         | A.N.S. / S.A.B.S. Specif | ication?                                |    |
| Is The Price |              | With the Specification?                           |                  |               | E.G. <i>E.G. 1day</i> |                          | loudoiti                                |    |
| Contact Pe   | erson;       | e <u>quote</u> may be directed to:                |                  |               |                       | nnical information ma    |   |    |

#### **DECLARATION OF INTEREST**

|                      | blood relationship, may make a limited quote or proposal). In v employed by the state, or to p declare his/her position in relation the bidder is employed by the legal person on whose evaluation and or adjudication.   | an offer or offers in terms of this invita-<br>view of possible allegations of favourit<br>ersons connected with or related to li-<br>ion to the evaluating/adjudicating auth<br>e state; and/or<br>behalf the bidding document is signe-<br>on of the quote(s), or where it is know- | sons having a kinship with persons er<br>ation to quote (includes a price quotation<br>ism, should the resulting quote, or par<br>them, it is required that the bidder or later<br>that the bidder or later<br>and, has a relationship with persons/a part<br>that such a relationship exists betwo | on, advertised competitive quote,<br>t thereof, be awarded to persons<br>his/her authorised representative<br>person who are/is involved in the<br>leen the person or persons for or |
|----------------------|---|---|---|--|
| 2.                   | In order to give effect to the ab-  | ove, the following questionnaire must   | be completed and submitted with the   | quote.   |
| 2.1.<br>2.2.<br>2.3. | Identity Number:<br>Position occupied in the Comp   |   | 2.4. Company Registration Number:   | ***************************************  |
| 2.8.                 | employee / persal numbers m<br>Are you or any person connect<br>I.If so, furnish the following part<br>Name of person / director / trus   | ust be indicated in paragraph 3 below<br>ted with the bidder presently employe<br>iculars:<br>tee / shareholder/ member:  | ed by the state?  | [TICK APPLICABLE]  YES NO  |
|                      | Name of state institution at whi<br>Position occupied in the state in   | ch you or the person connected to the<br>nstitution:  | e bidder is employed:Any other particulars:   |  |
| 2.8.2                | <ol><li>If you are presently employed in the public sector?</li></ol>   | ed by the state, did you obtain the app   | propriate authority to undertake remun  | erative work outside employment  YES   NO  |
| (Note:               | Failure to submit proof of such a   | f of such authority to the quote docum<br>nuthority, where applicable, may resu   | It in the disqualification of the quote.)   | <u> </u>   |
|                      | Did you or your spouse, or an state in the previous twelve m  | y of the company's directors / trustee onths?   | f:<br>s / shareholders / members or their sp  | ouses conduct business with the  |
| 2.10                 | Do you, or any person connect may be involved with the eval   | ted with the bidder, have any relation<br>uation and or adjudication of this quot   | ship (family, friend, other) with a perso<br>e?   | n employed by the state and who  |
| 2.11                 | . Are you, or any person connection and are made and a series of the state who made are series of the state who made are series of the series | cted with the bidder, aware of any rela<br>ay be involved with the evaluation and   | itionship (family, friend, other) between<br>I or adjudication of this quote?   | any other bidder and any person YES NO   |
| 2.12                 | <ul> <li>Do you or any of the directors<br/>or not they are bidding for this</li> </ul>   | / trustees / shareholders / members o   | f the company have any interest in any  | other related companies whether<br>YES NO  |
| 3.                   | Full details of directors / trus The Department Of Health wil to ensure that their details are  | tees / members / shareholders.<br>  validate details of directors / truste<br>  up-to-date and verified on CSD. If the  | es / members / shareholders on CSI<br>he Department cannot validate the inf<br>National Treasury Instruction Note 4 (a  | ormation on CSD, the quote will  |
| 4                    | DECLARATION   |   |   |  |
| I, T<br>FUI          | HE UNDERSIGNED (NAM<br>RNISHED IN PARAGRAPH   | E)<br>IS 2.   | CERTIFY   | THAT THE INFORMATION   |
|                      | CCEPT THAT THE STATE<br>OVE TO BE FALSE.  | MAY REJECT THE QUOTE OF   | R ACT AGAINST ME SHOULD T   | THIS DECLARATION   |
|                      | ne of bidder  | Signature   | Position  | Date   |
| ¹ºSta<br>a)<br>b)    | te" means – any national or provincial departme constitutional institution within the m Act, 1999 (Act No. 1 of 1999); any municipality or municipal entity;  | ent, national or provincial public entity or<br>eaning of the Public Finance Management   | c) provincial legislature; d) national Assembly or the national Counci e) Parliament.   | l of provinces; or   |

<sup>2&</sup>quot;Shareholder" means a person who owns shares in the company and is actively involved in the management of the enterprise or business and exercises control over the enterprise.

#### SPECIAL CONTRACT CONDITIONS OF QUOTATIONS

#### 1. AMENDMENT OF CONTRACT

1.1. Any amendment to or renunciation of the provisions of the contract shall at all times be done in writing and shall be signed by both parties.

#### 2. CHANGE OF ADDRESS

2.1. Bidders must advise the Department of Health (institution where the offer was submitted) should their address (domicilium citandi et executandi) details change from the time of bidding to the expiry of the contract.

#### 3. GENERAL CONDITIONS ATTACHED TO THIS QUOTATION

- 3.1. The institution is under no obligation to accept the lowest or any quote.
- 3.2. The price quoted must include VAT (if VAT vendor). However, it must be noted that the department reserves the right to evaluate all quotations excluding VAT as some bidders may not be VAT vendors.
- 3.3. The bidder must ensure the correctness & validity of quote:
  - (i) that the price(s), rate(s) & preference quoted cover all for the work/item (s) & accept that any mistakes regarding the price (s) & calculations will be at the bidder's risk
- 3.4. The bidder must accept full responsibility for the proper execution & fulfilment of all obligations conditions devolving on under this agreement, as the Principal (s) liable for the due fulfilment of this contract.
- 3.5. This quotation will be evaluated based on the 80/20 points system, specification & correctness of information. All required documentation must be completed in full and submitted.
- 3.6. Offers must comply strictly with the specification.
- 3.7. Only offers that meet or are greater than the specification will be considered.
- 3.8. Late quotes will not be considered.
- 3.9. Expired product/s will not be accepted. All products supplied must be valid for a minimum period of six months.
- 3.10. A bidder not registered on the Central Suppliers Database or verification has failed will not be considered.
- 3.11. All delivery costs must be included in the quote price, for delivery at the prescribed destination.
- 3.12. Only firm prices will be accepted. Such prices must remain firm for the contract period. Non-firm prices (including rates of exchange variations) will not be considered.
- 3.13. In cases where different delivery points influence the pricing, a separate pricing schedule must be submitted for each delivery point.
- 3.14. In the event of a bidder having multiple quotes, only the cheapest according to specification will be considered. Furthermore a verification will be done to identify if bidders have multiple companies and are quoting (cover-quoting) for this bid. In such instances only the cheapest bid according to specification will be considered.

#### 4. SPECIAL INSTRUCTIONS AND NOTICES TO BIDDERS REGARDING THE COMPLETION OF THIS QUOTATION.

- 4.1. Unless inconsistent with or expressly indicated otherwise by the context, the singular shall include the plural and vice versa and with words importing the masculine gender shall include the feminine and the neuter.
- 4.2. Under no circumstances whatsoever may the quotation/bid forms be retyped or redrafted. Photocopies of the original bid documentation may be used, but an original signature must appear on such photocopies.
- 4.3. The bidder is advised to check the number of pages and to satisfy himself that none are missing or duplicated.
- 4.4. Quotation submitted must be complete in all respects.
- 4.5. Any alteration made by the bidder must be initialled.
- 4.6. Use of correcting fluid is prohibited
- 4.7. Quotation will be opened in public as soon as practicable after the closing time of quotation.
- 4.8. Where practical, prices are made public at the time of opening quotations.
- 4.9. If it is desired to make more than one offer against any individual item, such offers should be given on a photocopy of the page in question. Clear indication thereof must be stated on the schedules attached.

#### 5. SPECIAL INSTRUCTIONS REGARDING HAND DELIVERED QUOTATIONS

- 5.1. Quotation shall be lodged at the address indicated not later than the closing time specified for their receipt, and in accordance with the directives in the quotation documents.
- 5.2. Each quotation shall be addressed in accordance with the directives in the quotation documents and shall be lodged in a separate sealed envelope, with the name and address of the bidder, the quotation number and closing date indicated on the envelope. The envelope shall not contain documents relating to any quotation other than that shown on the envelope. If this provision is not complied with, such quotations/bids may be rejected as being invalid.
- 5.3. All quotations received in sealed envelopes with the relevant quotation numbers on the envelopes are kept unopened in safe custody until the closing time of the quotation/bids. Where, however, a quotation is received open, it shall be sealed. If it is received without a quotation/bid number on the envelope, it shall be opened, the quotation number ascertained, the envelope sealed and the quotation number written on the envelope.
- 5.4. A specific box is provided for the receipt of quotations, and no quotation found in any other box or elsewhere subsequent to the closing date and time of quotation will be considered.

- 5.5. No quotation/bid sent through the post will be considered if it is received after the closing date and time stipulated in the quotation documentation, and proof of posting will not be accepted as proof of delivery.
- 5.6. Quotation documents must not be included in packages containing samples. Such quotations may be rejected as being invalid.

#### 6. SAMPLES

- 6.1. In the case of the quote document stipulating that samples are required, the supplier will be informed in due course when samples should be provided to the institution. (This decreases the time of safety and storage risk that may be incurred by the respective institution). The bidders sample will be retained if such bidder wins the contract.
- (i) If a company/s who has not won the quote requires their samples, they must advise the institution in writing of such.
- (ii) If samples are not collected within three months of close of quote the institution reserves the right to dispose of them at their discretion.
- 6.2. Samples must be made available when requested in writing or if stipulated on the document.
- (i) If a Bidder fails to provide a sample of their product on offer for scrutiny against the set specification when requested, their offer will be rejected. All testing will be for the account of the bidder.

#### 7. COMPULSORY SITE INSPECTION / BRIEFING SESSION

| 7.1.        | Bidders who fail to attend the compulsory meeting will be disqua                | lified from the e | evaluation process.                      |
|-------------|---|-------------------|--|
| (i)<br>(ii) | The institution has determined that a compulsory site meeting  Date/ Time Place |                   | take place                               |
| Instit      | ution Stamp:  | Institution Site  | e Inspection / briefing session Official |
|             |   | Full Name:        |  |
|             |   | Signature:        |  |
|             |   | Date:             |  |

#### 8. STATEMENT OF SUPPLIES AND SERVICES

8.1. The contractor shall, when requested to do so, furnish particulars of supplies delivered or services executed. If he/she fails to do so, the Department may, without prejudice to any other rights which it may have, institute inquiries at the expense of the contractor to obtain the required particulars.

#### 9. SUBMISSION AND COMPLETION OF SBD 6.1

9.1. Should a bidder wish to qualify for preference points they must complete a SBD 6.1 document. Failure by a bidder to provide all relevant information required, will result in such a bidder not being considered for preference point's allocation. The preferences applicable on the closing date will be utilized. Any changes after the closing date will not be considered for that particular quote.

#### 10. TAX COMPLIANCE REQUIREMENTS

- 10.1. In the event that the tax compliance status has failed on CSD, it is the suppliers' responsibility to provide a SARS pin in order for the institution to validate the tax compliance status of the supplier.
- 10.2. In the event that the institution cannot validate the suppliers' tax clearance on SARS as well as the Central Suppliers Database, the quote will not be considered and passed over as non-compliant according to National Treasury Instruction Note 4 (a) 2016/17.

#### 11. TAX INVOICE

- 11.1. A tax invoice shall be in the currency of the Republic of South Africa and shall contain the following particulars:
- (i) the name, address and registration number of the supplier;
- (ii) the name and address of the recipient;
- (iii) an individual serialized number and the date upon which the tax invoice is issued;
- (iv) a description and quantity or volume of the goods or services supplied;
- (v) the official department order number issued to the supplier;
- (vi) the value of the supply, the amount of tax charged;
- (vii) the words tax invoice in a prominent place.

#### 12. PATENT RIGHTS

The supplier shall indemnify the KZN Department of Health (hear after known as the purchaser) against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the goods or any part thereof by the purchaser.

#### 13. PENALTIES

- 13.1. If at any time during the contract period, the service provider is unable to perform in a timely manner, the service provider must notify the institution in writing/email of the cause of and the duration of the delay. Upon receipt of the notification, the institution should evaluate the circumstances and, if deemed necessary, the institution may extend the service provider's time for performance.
- 13.2. In the event of delayed performance that extends beyond the delivery period, the institution is entitled to purchase commodities of a similar quantity and quality as a substitution for the outstanding commodities, without terminating the contract, as well as return commodities delivered at a later stage at the service provider's expense.
- 13.3. Alternatively, the institution may elect to terminate the contract and procure the necessary commodities in order to complete the contract. In the event that the contract is terminated the institution may claim damages from the service provider in the form of a penalty. The service provider's performance should be captured on the service provider database in order to determine whether or not the service provider should be awarded any contracts in the future.
- 13.4. If the supplier fails to deliver any or all of the goods or to perform the services within the period(s) specified in the contract, the purchaser shall, without prejudice to its other remedies under the contract, deduct from the contract price, as a penalty, a sum calculated on the delivered price of the delayed goods or unperformed services using the current prime interest rate calculated for each day of the delay until actual delivery or performance.

#### 14. TERMINATION FOR DEFAULT

- 14.1. The purchaser, without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, may terminate this contract in whole or in part:
- (i) if the supplier fails to deliver any or all of the goods within the period(s) specified in the contract,
- (ii) if the supplier fails to perform any other obligation(s) under the contract; or
- (iii) if the supplier, in the judgment of the purchaser, has engaged in corrupt or fraudulent practices in competing for or in executing the contract.
- 14.2. In the event the purchaser terminates the contract in whole or in part, the purchaser may procure, upon such terms and in such manner as it deems appropriate, goods, works or services similar to those undelivered, and the supplier shall be liable to the purchaser for any excess costs for such similar goods, works or services.
- 14.3. Where the purchaser terminates the contract in whole or in part, the purchaser may decide to impose a restriction penalty on the supplier by prohibiting such supplier from doing business with the public sector for a period not exceeding 10 years.
- 15. FAILURE TO COMPLY WITH ABOVE WILL RESULT IN YOUR QUOTE BEING PASSED OVER.

### PREFERENCE POINTS CLAIM FORM IN TERMS OF THE PREFERENTIAL PROCUREMENT REGULATIONS 2017

This preference form must form part of all quotes invited. It contains general information and serves as a claim form for preference points for Broad-Based Black Economic Empowerment (B-BBEE) Status Level of Contribution

NB: BEFORE COMPLETING THIS FORM, BIDDERS MUST STUDY THE GENERAL CONDITIONS, DEFINITIONS AND DIRECTIVES APPLICABLE IN RESPECT OF B-BBEE, AS PRESCRIBED IN THE PREFERENTIAL PROCUREMENT REGULATIONS, 2017.

#### 1. GENERAL CONDITIONS

- 1.1 The following preference point systems are applicable to all quotes:
  - the 80/20 system for requirements with a Rand value of up to R50 000 000 (all applicable taxes included); and
- 1.2 The value of this quote is estimated to not exceed R50 000 000 (all applicable taxes included) and therefore the 80/20 preference point system shall be applicable.
- 1.3 Points for this quote shall be awarded for:
  - (a) Price; and
  - (b) B-BBEE Status Level of Contributor.
- 1.4 The maximum points for this quote is allocated as follows:

|   | POINTS |
|---|--------|
| PRICE   | 80     |
| B-BBEE STATUS LEVEL OF CONTRIBUTOR                | 20     |
| Total points for Price and B-BBEE must not exceed | 100    |

- 1.5 Failure on the part of a bidder to submit proof of B-BBEE Status level of contributor together with the quote, will be interpreted to mean that preference points for B-BBEE status level of contribution are not claimed.
- 1.6 The purchaser reserves the right to require of a bidder, either before a quote is adjudicated or at any time subsequently, to substantiate any claim in regard to preferences, in any manner required by the purchaser.

#### 2. **DEFINITIONS**

- (a) "B-BBEE" means broad-based black economic empowerment as defined in section 1 of the Broad-Based Black Economic Empowerment Act;
- (b) "B-BBEE status level of contributor" means the B-BBEE status of an entity in terms of a code of good practice on black economic empowerment, issued in terms of section 9(1) of the Broad-Based Black Economic Empowerment Act;
- (c) "bid" means a written offer in a prescribed or stipulated form in response to an invitation by an organ of state for the provision of goods or services, through price quotations, advertised competitive bidding processes or proposals;
- (d) "Broad-Based Black Economic Empowerment Act" means the Broad-Based Black Economic Empowerment Act, 2003 (Act No. 53 of 2003);
- (e) "EME" means an Exempted Micro Enterprise in terms of a code of good practice on black economic empowerment issued in terms of section 9 (1) of the Broad-Based Black Economic Empowerment Act;
- (f) "functionality" means the ability of a tenderer to provide goods or services in accordance with specifications as set out in the tender documents.
- (g) "prices" includes all applicable taxes less all unconditional discounts;
- (h) "proof of B-BBEE status level of contributor" means:
  - B-BBEE Status level certificate issued by an authorized body or person;
  - 2) A sworn affidavit as prescribed by the B-BBEE Codes of Good Practice;
  - 3) Any other requirement prescribed in terms of the B-BBEE Act;
- (i) "QSE" means a qualifying small business enterprise in terms of a code of good practice on black economic empowerment issued in terms of section 9 (1) of the Broad-Based Black Economic Empowerment Act;
- (j) "rand value" means the total estimated value of a contract in Rand, calculated at the time of bid invitation, and includes all applicable taxes;

#### 3. POINTS AWARDED FOR PRICE

#### 3.1 THE 80/20 PREFERENCE POINT SYSTEMS

A maximum of 80 points is allocated for price on the following basis:

$$Ps = 80 \left( 1 - \frac{Pt - P\min}{P\min} \right)$$
 Where

Ps = Points scored for price of bid under consideration

Pt = Price of bid under consideration
Pmin = Price of lowest acceptable bid

#### 4. POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

4.1 In terms of Regulation 6 (2) and 7 (2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

| B-BBEE Status Level of Contributo | or Number of points (80/20 system) |
|-----------------------------------|------------------------------------|
| 1                                 | 20                                 |
| 2                                 | 18                                 |
| 3                                 | 14                                 |
| . 4                               | 12                                 |
| 5                                 | 8                                  |
| 6                                 | 6                                  |
| 7                                 | 4                                  |
| 8                                 | 2                                  |
| Non-compliant contributor         | 0                                  |

| _ | DIE  | DECL   | A PART                       |      |
|---|------|--------|------------------------------|------|
| h | H111 | 1111-1 | $\alpha \omega \alpha \iota$ | и ил |
|   |      |        |                              |      |

- 5.1 Bidders who claim points in respect of B-BBEE Status Level of Contribution must complete the following:
- 6. B-BBEE STATUS LEVEL OF CONTRIBUTOR CLAIMED IN TERMS OF PARAGRAPHS 1.4 AND 4.1
- 6.1 B-BBEE Status Level of Contributor: = ......(maximum of 20 points)

| 0.1   | B BBEE Clared Edver of Continuation   |   |  |    |
|-------|---|---|--|----|
|       | claimed in respect of paragraph 7.1 must be in a<br>B-BBEE status level of contributor. | ccordance with the table reflected in paragraph | 4.1 and must be substantiated by relev | an |
| 7.    | SUB-CONTRACTING   |   | (Tick applicable box)                  |    |
| 7.1   | Will any portion of the contract be sub-contr   | racted?   | YES NO                                 |    |
| 7.1.1 | If yes, indicate:   | ,   |  |    |
| 8.    | ii) The name of the sub-contractor  | e subcontracted%<br>ontractor<br>E              | (Tick applicable box)                  |    |
|       |   | er i i e i iste in internation to to            | arms of time                           | _  |

iv) Specify, by ticking the appropriate box, if subcontracting with an enterprise in terms of Preferential Procurement Regulations, 2017:

Designated Country An EME or OSE which is at lest 51% armed by:

OSE

| Designated Group: An EME or QSE which is at last 51% owned by:       | EME   | QSE          |
|--|-------|--------------|
| Besignated Group, All Line of QOL Inflort of action of the office ay | <br>√ | \ \frac{1}{} |
| Black people   |       |              |
| Black people who are youth   |       |              |
| Black people who are women   |       |              |
| Black people with disabilities                                       |       |              |
| Black people living in rural or underdeveloped areas or townships    |       |              |
| Cooperative owned by black people                                    |       |              |
| Black people who are military veterans                               |       |              |
| OR   |       |              |
| Any EME  |       |              |
| Any QSE  |       |              |

| 9.  | DECLA       | RATION WITH REGARD TO COMPANY/FIRM  |   |
|-----|-------------|---|---|
| 9.1 | Name        | e of company/firm:  |   |
| 9.2 | VAT         | registration number:  |   |
| 9.3 | Comp        | pany registration number:   |   |
| 9.4 | TYPE        | OF COMPANY/ FIRM [TICK APPLICABLE BOX]  |   |
|     | 0<br>0<br>0 | Partnership/Joint Venture / Consortium One person business/sole propriety Close corporation Company (Pty) Limited   |   |
| 9.5 | DESC        | CRIBE PRINCIPAL BUSINESS ACTIVITIES   |   |
| 9.6 |             |   | v1  |
| J.O |             | PANY CLASSIFICATION [TICK APPLICABLE BOX<br>Manufacturer<br>Supplier<br>Professional service provider<br>Other service providers, e.g. transporter, etc.    | · · · · · · · · · · · · · · · · · · ·   |
| 9.7 | Total       | number of years the company/firm has been in bus  | siness:   |
| 9.8 | the B-      | he undersigned, who is / are duly authorised to do<br>BBE status level of contributor indicated in paragr<br>eference(s) shown and I / we acknowledge that: | o so on behalf of the company/firm, certify that the points claimed, based on raphs 1.4 and 6.1 of the foregoing certificate, qualifies the company/ firm for   |
|     | i) 1        | The information furnished is true and correct;  |   |
|     | ii) T       | The preference points claimed are in accordance w   | vith the General Conditions as indicated in paragraph 1 of this form;   |
|     | iii) l      | n the event of a contract being awarded as a resu-<br>be required to furnish documentary proof to the sat   | It of points claimed as shown in paragraphs 1.4 and 6.1, the contractor may isfaction of the purchaser that the claims are correct;   |
|     | iv) li<br>h | f the B-BBEE status level of contributor has been on<br>the not been fulfilled, the purchaser may, in addition  | claimed or obtained on a fraudulent basis or any of the conditions of contract on to any other remedy it may have –   |
|     | (a)         | disqualify the person from the bidding process;   |   |
|     | (b)         |   | d or suffered as a result of that person's conduct;   |
|     | (c)         |   | nich it has suffered as a result of having to make less favourable  |
|     | (d)         | who acted on a fraudulent basis, be restricted to   | nareholders and directors, or only the shareholders and directors<br>by the National Treasury from obtaining business from any organ<br>fter the <i>audi alteram partem</i> (hear the other side) rule has been |
|     | (e)         | forward the matter for criminal prosecution.  |   |
|     | WITN        | IESSES  | SIGNATURE(S) OF BIDDERS(S)  |
|     | 1           |   |   |
|     | 2           |   | ADDRESS   |
|     |             |   |   |

### Paediatric Patient Record

|               | Birth Registration/ID Num               | ber:                  |                            |
|---------------|---|-----------------------|----------------------------|
| Name:         |   | OP number:            |                            |
| Address:      |   | IP number:            |                            |
|               | •                                       | Date of birth:        | V-4.                       |
| Phone number: | • | Gender: Male / Female | (use sticker if available) |

|                   | •                    | Admissions Register       |            | •                        |
|-------------------|----------------------|---------------------------|------------|--------------------------|
| Date of admission | Date of<br>discharge | Main reason for admission | ICD Code   | Follow up place and date |
|                   | -                    |                           |            |                          |
|                   | ,                    |                           |            |                          |
|                   |                      |                           |            |                          |
| •                 |                      | ,                         |            |                          |
|                   |                      |                           |            |                          |
|                   |                      |                           |            |                          |
|                   |                      |                           |            |                          |
|                   |                      |                           |            |                          |
|                   |                      |                           | ,, ,       |                          |
| 7.                |                      |                           | <u> </u> : |                          |

| Date | Chronic or lifelong problem | ICD Code | Management |
|------|-----------------------------|----------|------------|
| •    |                             |          |            |
| ·    |                             |          |            |
|      | ·                           |          |            |
|      |                             |          |            |
|      |                             |          |            |
| -    | :                           |          |            |
|      |                             |          |            |

Reason

Dose

Date

Reason

Dose

Date

Additional-ರಂses

| Till screening and assessment  | ١        | • • •                |                    |          | POF       | O        |   | Folde        | er No:    |  |                     | Q  |
|--|----------|----------------------|--------------------|----------|-----------|----------|---|--------------|-----------|--|---------------------|--|
| Deta of assissment   T-Businest Display   T-Busin   |          |                      | -d accorem         | <br>ent  |           |          |   |              |           |  |                     | ء<br>1                                       |
| Persistent cough > 2 weeks Persistent cough > 2 weeks Patigue / reduced playfulnes Perver every day for 2 z weeks Perver every day for 3 z weeks Perver every day for 4 z weeks Perver eve | TB       |                      |                    |          | -         |          |   |              |           |  |                     |  |
| Persistant Cough > 2 weeks   |          |                      |                    |          |           |          |   |              |           |  |                     |  |
| Persistent cough > 2 weeks   |          |                      |                    |          |           |          | Ø100  | <u> </u>     | 100       | <b>%/®</b>                                     | ଡ/®~                | ]  |
| Fever every day for 2 weeks    Fever every day for 2 weeks   |          |                      |                    |          |           |          |   |              |           | <b>%/</b> ®                                    | %/₩                 |  |
| Not growing well (checkgrowth chard   O / O /  |          |                      |                    |          |           |          |   |              |           |  |                     |  |
| Not growing well (checkgrowtchant)  Clinical signs of TB  Mantoux (mm)  CXR  TB assessment (Grobe one option clonby) Needs IPT Active TB Active TB Active TB Active TB  Social History  Primary caregiver: Qualifies for Grant: Clinical spoot of Grant Start date:  Food Security  Currently breast fed: Yes / No /?  Family History  Mother: Other: Other: Other: Other: Other: Other: Other: Other: Significant Past Medical History Hospital Folder number  Clinical problem  Clinical problem  Clinical problem  Outcome/Long term plan  Developmental History (enter age attained)  Schooling  Year School/centre  Grade  Any problems   |          |                      |                    |          |           |          |   |              |           |  | ∅/®                 |  |
| Clinical signs of TB   Clinical signs of TB   Clinical signs of TB   Clinical signs of TB   Clinical problem   Clinical problem   Clinical problems   Clinical probl   |          | Not growing well (   | checkgrowth chart) |          |           |          |   |              |           |  |                     | Γ.   |
| No TB currently   No TB currently   No TB currently   No TB currently   Needs IPT   Needs IPT   Needs IPT   Active TB   Acti   |          | : Cli                | nical signs of TB  |          | D/W :     |          | W/W   |              | 10        |  |                     | 7  |
| TB assessment (Gree one options between the comprehensive TB Care Record in patients folder Social History  Primary caregiver:  Occupation:  Name: Occupation:  Cell phone:  Number of Dependents:  No TB currently Needs IPT Active TB Active TB Active TB Needs IPT Acti |          |                      | Mantoux (mm)       | <br>     |           |          |   | •            |           |  |                     | 1  |
| Primary caregiver: Occupation: Name: Occupation: Number of Dependents: Number of Dependents: Number of Dependents: Number of Dependents: Foster Care Grant Start date: Food Security Currently breast fed: Yes / No/? Food supply adequate: Yes / No/? Needs nutrition support: Yes / No/? Family History Mother: Father: Other: Significant Past Medical History Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Taked:  Schooling  Year School/centre Grade Any-problems   |          | (Cin                 | TB assessment      | ٠ )      | Needs IPT | Į.       | Needs IP I  | Ne           | eds IPT   | Needs IPT                                      | Needs IPT           |  |
| Primary caregiver: Occupation: Name: Occupation: Number of Dependents: Number of Dependents: Number of Dependents: Number of Dependents: Foster Care Grant Start date: Food Security Currently breast fed: Yes / No/? Food supply adequate: Yes / No/? Needs nutrition support: Yes / No/? Family History Mother: Father: Other: Significant Past Medical History Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Taked:  Schooling  Year School/centre Grade Any-problems   | **[:     | nsert comprehensive  | B Care Record in p | atient'  | s folder  |          |   |              |           |  | <br><u>:</u>        |  |
| Primary caregiver:    Name:   Occupation:   Cell phone:   Number of Dependents:  | S        | ocial History        | ·                  |          |           | -==      | -=  |              |           |  |                     | $\neg$                                       |
| Primary caregiver:  Household Income:  Qualifies for Grant: Start date:  Food Security  Currently breast fed: Yes / No/?  Food supply adequate: Yes / No/?  Needs nutrition support: Yes / No/?  Family History  Mother: Father: Other:  Significant Past Medical History  Hospital Folder number  Clinical problem  Outcome/Long term plan  Developmental History (enter age attained)  Smiled:  Schooling  Year School/centre Grade  Any problems  | Γ        |                      | Name:              |          |           |          | ·<br>   |              | Relations | hip: ———                                       |                     |  |
| Household Income:  Qualifies for Grant:  Child Support Grant  Care Dependency Grant  Foster Care Grant  Start date:  Food Security  Currently breast feet: Yes / No/?  Family History  Mother:  Father:  Other:  Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled:  Sat:  Crawled:  Walked:  Taiked:  Schooling  Year School/centre Grade  Any problems  | Pr       | rimary caregiver:    | Occupation         | :        |           |          | -   |              | Cell phor | ne:  |                     | {  |
| Qualifies for Grant: Child Support Grant Care Dependency Grant Foster Care Care Late Circuit Start date:  Food Security  Currently breast fed: Yes / No /? Food supply adequate: Yes / No /? Needs nutrition support: Yes / No /?  Family History  Mother: Father: Other: Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any problems  | -        |                      |                    |          |           |          |   |              | Number    | of Dependents:                                 |                     |  |
| Start date:  Food Security  Currently breast fed: Yes / No /? Food supply adequate: Yes / No /? Needs nutrition support: Yes / No /?  Family History  Mother: Father: Other: Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any problems   | $\vdash$ | •                    | 11 1               |          | t Crost   |          | Care De   | penden       | cy Grant  | Fost   | er Care Grant       |  |
| Food Securify  Currently breast fed: Yes / No /? Food supply adequate: Yes / No /? Needs nutrition support: Yes / No /?  Family History  Mother: Father: Other:  Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems   | 0        | Qualifies for Grant: | Child              | Sup      | OOLGIANG  |          | · .   | <u> </u>     |           | •  |                     |  |
| Currently breast fed: Yes / No/? Food supply adequate: Yes / No/? Needs nutrition support: Yes / No/?  Family History  Mother: Father: Other:  Significant Past Medical History Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  | S        | itart date:          |                    |          | 1         |          |   | <u> </u>     |           |  |                     |  |
| Family History  Mother: Father: Other:  Significant Past Medical History Hospital Folder number Clinical problem —Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  | Ĭ        | Food Securit         | У                  |          |           |          |   | <del>,</del> |           | · · · · · · · · · · · · · · · · · · ·          | unnorts Vac / Na    | /2   |
| Mother: Father: Other:  Significant Past Medical History Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any problems   | Γ        | Currently breas      | t fed: Yes / No/   | ?        | Food supp | ly ac    | dequate: Yes  | No/?         |           | leeds nutrition si                             | upport. Tes / Tes / |  |
| Mother: Father: Other:  Significant Past Medical History Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any problems   |          | Family Histo         | ry                 | 7        |           |          |   |              |           |  | ***                 |  |
| Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  | -        |                      |                    |          |           | ~···     |   |              |           |  |                     |  |
| Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  | f        | Father:              |                    |          |           |          |   |              |           |  |                     |  |
| Significant Past Medical History  Hospital Folder number Clinical problem Outcome/Long term plan  Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  | H        |                      |                    | 47-4     |           |          | ··· · · · · · · · · · · · · · · · · ·                         |              | ,         | the same management and the same of            |                     | <u>-                                    </u> |
| Hospital Folder number Clinical problem Outcome Long term part of the problem outcome Long term part | ~ ; 1    |                      | lact Madics        | i H      | story     |          |   | · · ·        | . :       | مسيد جي انها برنسون<br>انها د انها د انها بيان |                     | <del></del>                                  |
| Developmental History (enter age attained)  Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  | ,        |                      |                    | _        | C         | inic:    | al problem  |              |           | Outcome/Lo                                     | ng term plan        |  |
| Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  |          | Hospital             | Folder number      | =        |           |          |   |              |           |  |                     |  |
| Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  |          |                      |                    | ┼        |           |          |   |              |           |  |                     |  |
| Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  |          |                      |                    | <u> </u> | <u> </u>  |          |   | <u>.</u>     |           |  |                     |  |
| Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  |          |                      |                    |          | j         | 24.5     | Marie - 100 mayor 1 may 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 | <del></del>  |           |  |                     |  |
| Smiled: Sat: Crawled: Walked: Talked:  Schooling  Year School/centre Grade Any-problems  |          | Developm             | ental His          | tor      | y (entei  | a        | ge attair   | red)         |           | · · · · · ·                                    |                     | <u> </u>                                     |
| Schooling Year School/centre Grade Any-problems  |          |                      |                    |          |           |          |   |              | Walked:   |  | Talked:             |  |
| Year School/centre Grade Any problems  |          |                      | 3                  |          |           |          |   |              |           | <u>,</u>                                       |                     |  |
|  |          |                      |                    | re       | Grade     |          |   |              | -An       | y-problems                                     | -                   | <u> </u>                                     |
|  |          | , <u></u>            |                    |          | · .       | -        | _   |              |           |  |                     |  |
|  |          |                      |                    |          |           | $\dashv$ |   |              |           |  | ·                   |  |

| •   |                            |                     | •                                 | •                    |
|---|----------------------------|---------------------|-----------------------------------|----------------------|
|   | •                          | ••                  |                                   |                      |
|   | •                          |                     | Folder No:                        |                      |
| Name:   |                            |                     | •                                 | •                    |
|   | <del></del>                |                     |                                   | •                    |
| Developmental screen                          | :                          |                     |                                   | r a tr _t _t helent∧ |
|   | de la Leine de la constant | and annua           | ally if over two years (using the | Molteno chan below). |
| Screen development at every visit for a child | under two yea              | is or age and annua |                                   | -5                   |
|   |                            | 1                   | 1 i                               |                      |

| Care dependent<br>Special need   | Yes/No | tes/No   |        |        |          |
|----------------------------------|--------|----------|--------|--------|----------|
| Development quotient (DA/CA)     |        | Yes / No | Yes/No | Yes/No | Yes / No |
| =GM+FM+C+P&S/4)                  |        |          |        |        |          |
| Developmental age in months (DA) |        |          |        |        |          |
| Personal & social (months)       |        |          |        | •      |          |
| Communication (months)           |        |          |        |        |          |
| Fine motor (months)              |        |          |        |        |          |
| Gross motor (months)             |        | •        | ·      |        |          |
| Age in months (CA)               |        |          |        |        | •        |
| Date of assessment               |        |          |        | -      |          |

|              |  | Fine Motor   | t Chart (0 - 10 years) Communication   | Personal Social  |
|--------------|--|--|--|--|
| Age          | Gross Motor  |  | · · · · · · · · · · · · · · · · · · ·  | Itemates between drowsiness and  |
| lewborn      | Ventral suspensions fread at ope, the  | lands fisted<br>loses eyes to sudden bright<br>ght                                   | Starties to sudden loud noises a   | lert wakefulness   |
| 5 weeks      | oull to site some head control   | itares<br>Follows horizontally to 90 0   | Statue response  | miles at mother  |
| months       | Pulls to sit: little or no head lag Prone:<br>supports on forearms, lifts head,  | follows through 180°<br>Holds rattle when placed in<br>hand                          | Coos, chuckles and squeals   | excited when sees mother Obvious pleasure at being handled                                       |
| <u>.</u> 6 . | Pulls to sit: braces shoulders and pulls Prone: Lifts head and chest up Supports on externded arm Palls from supine to prone | Reaches for and grasps toy<br>Transfers toy from one hand to<br>the other            | Initiates conversation   | Takes everything to the mouth<br>Pats mirror image   |
| 9            |  | Immediately reaches out and<br>holds a cube in each hand<br>Exploratory mouthing     |  | Stranger anxiety<br>Holds cup  |
| 10           | Pulls to stand, walks with assistance  | Picks up small object between<br>finger and thumb<br>Clicks two cubes together       | Waves bye-bye  | Plays peek-a-boo with mother.  |
|              | Beer walks, walks around rumiture  | Disease grace releases object of   |  | Finger feeds<br>Pushes arm into sleeve   |
| <u>. 12</u>  | lifting one foot and stepping sideways.  | request  | 2-3 words with meaning   |  |
| 15           | may walk alone  Walks alone – uneven steps, arms out- for balance  | 2 aubě tower   | Jabbers with expression Uses 5 words (other than mama, dada)   | Pulls off socks; Holds and drinks from a cup; Attempts to feed with a spoon - spills most        |
| 18           | Walks well, arms down<br>Pulls a toy: Throws a ball  | Completes simple form board with reversal (trial and error)* 3-4 cube tower          | Points to one picture  | Indicates wet / dirty nappy<br>Pulls up pants<br>Handles spoon and cup well                      |
| 24           | Climbs on a chair  Runs  Walks up and down steps two feet per step   | 6 cube tower and train   | Combines 5 words, <50 words , Uses<br>pronours, I, you, me<br>Points to 5 body parts<br>Names 3 picture                        | Spoon feeds without spilling<br>Clean and dry by day<br>Looks at books                           |
| . 36         | Walks up steps one foot per step, and down 2 feet per step   |  | Knows name, gender Talks incessantly Digit repetition (3) Names 8 picture cards  | Dry at night<br>Dresses - needs help with buttons  |
| -48          | Stands on preferred foot (3-5s) Hops<br>on preferred foot<br>Up and down stairs one foot per step                            | COPIES   | Sentence repetition; Knows full name<br>Recognises colours<br>Names 12 picture cards<br>Obeys: ball on, under, behind, at side | Eats with spoon and fork Dresses<br>and undresses<br>Washes and dries hands<br>Make-believe play |
| 60           | Catches ball 2/3  Walks easily on a narrow line Hops on each foot - 20 times   | Copies A, D Builds steps (6 – 10 cubes) Draws a man, full features                   | Fluent speech<br>3 opposites - lady, big and hot<br>Comprehends cold, tired, hungry  | Dresses and undresses on own<br>play - group of 4-5<br>Chooses own friends                       |
| 72           | Walks backwards along a straight line<br>(10 paces)<br>Sits up without the p of hands  | Capies ◆, ⊠ Builds 10 cube steps   | Word definition (5) Compositions - door, shoes, spoon Knows birthday, address  | Co-operative play - leadership ar<br>division of labour  |
| 7-8y         | iumps feet together  | Writes name, draws a perso<br>facial features, limbs correct<br>align to body, hands | , laks sentences of 10 symbols   | One special friend Dresses and undresses without l s, Takes full responsibility for personal     |
| 9-10         | rs Runs downstairs   | Writes 3 word sentences  | Produces all speech sounds including z and ng  | care   |

-----Cotrimexazole (yes/no)

| - A                                     |                |                          |              |                                      |  |                                |                  |                 |             |              |                       |
|---|----------------|--------------------------|--------------|--------------------------------------|--|--------------------------------|------------------|-----------------|-------------|--------------|-----------------------|
| Name:                                   |                |                          |              |                                      |  | Folder                         | . ynwper:        | <u>,</u>        |             |              |                       |
|   |                |                          | Н            | IV                                   | CARE REC   | ORD                            |                  |                 |             |              |                       |
| HIV EXPOSURE, PRI                       | EVENTION A     | ND IDENTIFI              | CATION       |                                      |  |                                | ·                |                 | - 1         |              |                       |
| Mother                                  | Date           | Re                       | sult         |                                      | Ch   | ild ·                          | <u> </u>         | ate<br>———      | Ag          | e            | Result                |
| HIV Serology                            |                |                          |              |                                      | PC   | R 6 weeks ald                  | Date:<br>Lab no: | ·               |             |              |                       |
| 1 <sup>st</sup> CD4                     |                |                          |              |                                      | PCR <sup>6</sup> / <sub>52</sub> a<br>breast fee | Date:<br>Leb no:               |                  |                 | •           | • •          |                       |
| Lowest CD4                              |                |                          |              |                                      |  | R∋pid 1                        |                  | •               |             |              |                       |
| Maternal Care                           | Date           | <br>circle approp        | riate)       |                                      |  | Rapid 2                        |                  |                 |             |              |                       |
| Lifelong ART                            | r              | notgiv∈n un              | known        |                                      |  | ELISA                          |                  |                 |             |              | <u>.</u>              |
| AZT from 14/40                          | r              | ot given un              | known        |                                      | Chilo  | Care                           | Date             | started         | D           | ate si       | topped                |
| Intrapartum ART                         | r              | not given un             | known        |                                      | Exclusive l                                      | reast feeding                  |                  |                 |             |              | <u>.</u>              |
| Outcome fo                              | r child (ci    | rcle appropri            | rte)         |                                      |  | VP from birth                  | <u> </u>         |                 |             |              |                       |
| HIV infected                            |                | IV Uninfect              |              |                                      | Cotrimoxa  | ızole fram ⁵/sz                |                  |                 |             |              |                       |
| ART ELIGIBILITY &                       | INITIATION     |                          |              |                                      |  |                                |                  | ·               |             |              | ••                    |
| Eligibility cr                          |                | Tick to STA              | RT ART       |                                      |  | Pre-AR                         | T baselii        | њ сопс          | lition      |              |                       |
|   | Age < 1 year   |                          |              |                                      |  | <b>⊂</b> D4                    | Date:            | •               | Resu        | lt:<br>      |                       |
|   | 1-5 years      |                          |              |                                      |  | Viral Load                     | Date:            |                 | Resu        | (t:          |                       |
| WHO Clinical                            | Stage 3 or 4   |                          |              |                                      | :WHO   | Clinical Stage                 | Date:            |                 | Stage       | 21           |                       |
|   | CD4 ≤ 25%      |                          |              |                                      |  | ART sup                        | ervisor (r       | esponsible      | ccregiver)  |              |                       |
| CD4 < 75                                | 50 cells/mm³   |                          |              | <u> </u>                             | Narme:   |                                |                  |                 |             |              |                       |
|   | 5 – 15 years   |                          |              |                                      | Rela tionship:                                   |                                |                  | Cell:           |             |              | <u>.</u>              |
| .WHO Clinical                           | Stage 3 or 4   |                          |              | ART literacy (adherence counselling) |  |                                |                  |                 |             |              |                       |
| CD4 < 35                                | 50 cells/mm³   |                          | •            | !                                    | Site:  | ·                              | <del></del> -    | Date re         | ady:        |              |                       |
| Fast-track eli                          |                | Tick to FAST             | TRACK        | .                                    |  | T I                            | ART initi        | ation           | <del></del> |              |                       |
|   | Age < 1 year   |                          |              |                                      | Site:<br>  |                                | Date:            |                 | . Folde     | er no:       |                       |
| · WHO Cli                               | nical Stage 4  |                          |              | L                                    |  | Al                             | RT contin        | nuation         |             |              |                       |
| MDR/XDR                                 | Tuberculosis   |                          |              |                                      | Site:  |                                | Date:            |                 | Folde       | er no:       |                       |
| HIV CARE (CIRCLE A                      | PPROPRIATE)    |                          |              |                                      |  |                                | ,,,              |                 | ·           |              |                       |
|   | imen: 1st Line | ·                        |              |                                      | ART Regim  | <del></del>                    |                  |                 | keliriou    |              | utrition              |
| -··. <-3 years old •                    | ≯·3 years      | old & > 10kg             | <            | 3 ys                                 | ears old   | >3 years old                   | & > 10kg         | lf TBe          | ccluded     | All          | children              |
| Abacavir (ABC)                          | Ąbacz          | avir (ABC)               | Consult      | local                                | referral centre                                  | Zidovudine                     |                  | (NH pro         |             |              | tra food,<br>itamins, |
| Lamivudine (3TC)<br>Lopinavir/Ritonavii |                | idine (3TC)<br>enz (EFZ) |              |                                      | HIV expert)                                      | Didan osin<br>Lopinavir/Ritton |                  | uou<br>I Adeiam |             |              | worming               |
| (LPV/r)                                 | , E19AII       |                          |              |                                      |  |                                |                  |                 |             |              |                       |
| HIV PROGRESS                            |                |                          |              |                                      |  |                                |                  |                 |             |              |                       |
|   |                | Date:                    |              |                                      |  | <u> </u>                       |                  |                 |             | <u> </u>     |                       |
|   |                | ble overleaf)            | ž.           |                                      |  |                                |                  |                 |             |              |                       |
| CD4 (< 5 years:                         |                |                          | E            |                                      | <u> </u>   |                                |                  |                 |             | <u> </u><br> |                       |
|   |                | (copies/ml)              | <del> </del> |                                      |  |                                |                  |                 |             | -            |                       |
| Disclosure to child                     |                |                          | 1            |                                      |  |                                |                  |                 |             |              |                       |
| Develo                                  | pment (dela    | yed/normal)              |              |                                      |  |                                |                  | ·               |             | - +-         | `<br><u></u>          |



|           | WHO PAEDIATRIC HIV CLINICAL STAGING (FOR CHILDREN <15 YEARS AND LABORATORY CONFIRMED HIV INFER   |
|-----------|--|
|           | STRONG FOR CHILDREN <15 YEARS AND LARGE ATOMY SOLUTION   |
|           | Asymptomatic Asymptomatic  |
|           | Persistent generalized lymphadenopathy   |
|           | Sylvania Syl |
|           |  |
|           | Unexplained, persistent hepatosplenomegaly   |
|           | Papular pruritic eruptions Seborrhoeic dermatitis  |
|           | Cebotthoeic delmaitis  |
| ŀ         | Extensive human papilloma virus infection  |
| F         | Extensive molluscum contagiosum  Fungal nall infections  |
| F         | Recurrent oral ulcerations   |
| - 1       | ineel pingipal on the control of the |
| - 17      | ineal gingival erythema (LGE)<br>Ingular chelitis  |
| H         | permined   |
| li        | Inexplained, persistent parotid enlargement<br>lerpes zoster   |
| F         | ACTIVIDATION of character Data / W   |
|           | ecurrent or chronic RTIs (otitis media, otomboea, sinusitis, tonsillittis)   |
|           |  |
| IV        | oderate unexplained malnutrition not adequately responding to standard therapy   |
| ļ.        | nexplained persistent diamhoea (14 days or more)   |
| 1 - 1     |  |
| PE        | resistent oral candidiasis (after first 6-8 weeks of life)   |
| J 011     | at righty leukopiakia  |
| Act       | rie necrotizing ulcerative gipgivitis / periodontitis  |
| , 4       | (UDIDIA 1D   |
| 100       | erculous lymphadenopathy (axillary, cervical or inguinal)  |
| OEV       | ere recurrent presumed bacterial pneumonia   |
| <u>~~</u> | ADIGU(C) 202000 (-0  |
| S.m.      | priorition interesting (<500/mm²) &/or thrombocytopenia (<5000/mm²) for > 1/12   |
| -y 111    | ptomatic lymphoid interstitial pneumonitis (LtP)   |
| es raic   |  |
| juex      | plained severe wasting, stunting or severe malnutrition not ade quately responding to standard therapy   |
| neu       | mocystis pneumonia   |
| есш       | rent severe presumed bacterial infection (e.g. empyema, pyormyositis, bone/joint infection, meningitis, but not pneumonia) oulmonary TB  |
| hron      | ic herpes simplex infection (orolabial or cutaneous of more then 1 month's duration, or visceral at any site)  It is surround  |
| cital     | pulmonary TB   |
| apos      | r's sarcoma  |
| sop       | hageal candidiasis(or candidiasis of trachea, bronchi, or lungs)   |
|           |  |
|           |  |
| V in      | fection (retinitis or infection of a   |
| гарц      | Imonary cryptococcosis including meningitis  |
| dis       | seminated endemic mycosis (e.g. extrapulmonary histoplasmosis, coccidiomycosis, penicilliosis)   |
| onic      | cryptosporidiosis coccidiomycosis pecining to the company histoplasmosis, coccidiomycosis  |
|           | 1003000025   |
| emir      | nated non-tuberculous myrobocia i i i i  |
| 111 00    | TOVEGODURIES FOR STATE   |
| bra[      | or B cell more-Hodokin's lives to  |
| 200       | Ve multipocal leukaspeart I i  |
| issoi     | ciated cardiomyopathy or HIV-associated nephropathy  |
|           | лерпгораthy  |

| TO THE PARTY OF TH | ט               |           |           |           |
|--|-----------------|-----------|-----------|-----------|
| Current carer  | Carer's partner | Sibli- #  |           |           |
| Name:  |                 | 5ibling 1 | Sibling 2 | Sibling 3 |
| HIV Status (circle) +/-/?  | . +/-/?         |           |           |           |
| The state of the s |                 | +/-/+     | +/-/2     | +/-/      |
| ****   | • • • •         | `         |           |           |

| Health: KwaZulu-Natal  | n Reference Mumber               |             |                  |          |             |                   |                   |
|--|----------------------------------|-------------|------------------|----------|-------------|-------------------|-------------------|
| 言。<br>Health Kwasuluriden  |                                  |             | Eolder [         | √umb∈    | эт:         |                   |                   |
|  |                                  |             |                  |          |             |                   |                   |
| me:  | ENSIVE CHILDHOOD                 | TBA:        | SSESSMEN         | IT (PAG  | €1)         |                   | 1                 |
| COMPREHE TB Assessment: Tick list for ALL chi  | INSI VE CHIEFY                   | ENTTI Y.    | AND CHECK        | TB STAT  | US IN ROAD  | TO HEALTH BOOK    | LET)              |
| . TB ASSESSMENT: TICK LIST FOR ALL CHI   | LDREN (PERFORM FREQU             |             | 1                |          |             |                   |                   |
| •  |                                  |             |                  |          |             |                   |                   |
| -IV infected   |                                  |             | <del> </del>     | _        |             |                   |                   |
| - United   |                                  |             |                  |          |             |                   |                   |
| Primary caregiver fit withecode<br>Regular or close contact with someone who               | has TB (see overleat)            |             |                  |          |             |                   |                   |
| Previously treated for TB  |                                  |             |                  |          |             |                   |                   |
| Persistent cough > 2 weeks   |                                  |             |                  |          |             |                   |                   |
| Persistent cought > 2  |                                  | L           |                  |          |             |                   |                   |
| Fatigue / reduced playfulness  |                                  | <u> </u>    |                  |          |             |                   |                   |
| Fever every day for > 2 weeks  |                                  |             |                  |          |             |                   | 1                 |
| Not growing well (look at growth chart) Weight for Height Z-score (WHZ) < -2 or V          | Veight < 3 <sup>rd</sup> centile |             |                  |          |             | <del>-</del>      | +                 |
| Weight for Height Z-score (VHZ) < 2.5  |                                  | 1           |                  |          |             |                   | +1                |
| Project nack masses > 2cm x 2cm  |                                  | 1           |                  |          |             |                   |                   |
| Signs of extra-pulmonary TB (e.g. gibbus   | detot und)                       | <del></del> |                  |          |             |                   |                   |
| L CVD guggpsis TB  |                                  | +1          |                  |          |             |                   |                   |
| Suspected TB (If any Of  | <u>VE</u> risk above is present  | 41          |                  |          |             |                   | ·                 |
| 2. TB INVESTIGATIONS: CHECK FOR A  | NY CHILD WITH "SUSPE             | CLED        | <u></u>          |          | •           | -                 |                   |
| 2. TB INVESTIGATIONS: CITE   | Date                             | :           |                  |          |             | <u>-</u>          |                   |
| in right   |                                  |             |                  | <u> </u> |             |                   |                   |
| Skin test (Mantoux record in mm)   | Lymphadenopathy                  | _           |                  | <u> </u> |             |                   |                   |
|  | Bronchial compression            | n           |                  | <u> </u> | ·           |                   |                   |
| Chest X-ray checklist  (the hallmark of paediatric pulmonary TB is                         | Consolidation/collaps            |             | \                |          |             |                   |                   |
| mediastinal lymphodenopathy)   | Miliary pattern                  |             | T                |          |             | Opening           |                   |
|  |                                  |             | Date             | Cel      | l count an  | pressure          |                   |
| CSF: Lumbar puri<br>(Do in <u>All</u> children with clinical meningit                      |                                  | ary         | Date             |          |             |                   |                   |
| (Do in <u>ALL</u> children with clinical meningn<br>TB, if/when there are no signs of rais | ed intracranial pressure)        |             |                  | 1        |             |                   | <u> </u>          |
| TB, if/when there are no signs of the status: Decide For All CH                            |                                  |             | 2/ (             | IDGEME   | TCOMBININ   | GTB ASSESSMENT &  | INVESTIGATIONS)   |
| TRISTATING DECIDE FOR ALL CHI  | LDREN WITH "SUSPECT              | LED IR      | (CUMCALTE        |          |             |                   |                   |
| <u></u>  |                                  |             |                  |          |             |                   |                   |
| No TB currently (Co  | ntinue regular TB risk assess    | ments)      |                  |          |             |                   |                   |
| *Needs IPT (Notify, Isoniazid Preventativ  | e Therapy for 6 months: OVI      | ERLEAF)     |                  |          |             |                   |                   |
| #Needs I/1 (Notify, Boundary)  | (Notify, Classify & Treat: OV    | ERLEAF)     |                  |          |             |                   |                   |
| *Needs IPT: Mantoux positive and/o   | r contact with someone i         | with TB,    | and <u>no</u> TB | sympto   | ms or Signs | ш                 | ,                 |
|  |                                  |             |                  |          |             |                   |                   |
| b) HIV infected children   |                                  |             |                  |          |             |                   |                   |
| 4. TRACK TB SPECIMENS  |                                  |             | TB-PCR           | <u> </u> | Microscopy  | Culture           | Sensitiv          |
| Specimen/Site  | Date Lab ID                      |             |                  |          |             |                   |                   |
| 1st GW / Sputum / IS   |                                  |             |                  |          |             | <u> </u>          |                   |
| z <sup>nd</sup> GW / Sputum / IS   |                                  |             |                  |          |             |                   |                   |
| 3 <sup>rd</sup> GW / Sputum  |                                  |             |                  |          |             |                   |                   |
| CSF / Pleural fluid / Ascites  |                                  |             |                  |          |             |                   | DCR +ve: cultur   |
| FNA/Biopsy   |                                  | ultura -V   | e: clinical di   | agnosis  | Defini      | te: Smear +ve; TB | -FULL EVEN CALCUL |

Probable: Smear -ve; T8-PCR -ve; culture -ve; clinical diagnosis

ĖΝ∀\Bjobzλ TB confirmation


| N                     |                |                                       |                     |   |                          |  |                            |  |            |                             |                    |             | O/A  | ica reco             | ros: Paedia         |
|-----------------------|----------------|---------------------------------------|---------------------|---|--------------------------|--|----------------------------|--|------------|-----------------------------|--------------------|-------------|--|----------------------|---------------------|
| Name                  | :              | · <u> </u>                            |                     |   |                          |  |                            |  | Folde      | r Numb                      | er:                |             |  |                      |                     |
|                       |                |                                       |                     | Dyn.                                    | AMIC CI                  | HILDHO   | od TB N                    | NANAG  | EMENT      | (PAGE 2)                    |                    |             |  |                      | <del>'</del>        |
|                       | GISTE          | R& NOTIFY                             |                     |   |                          |  |                            |  |            | (11.00.2)                   |                    |             |  |                      |                     |
| Date:                 |                | Site:                                 |                     |   | Blue C                   | ard filled                                       | in: Y/i                    | Not  | ification  | no:                         | ·                  | Sig         | n,   |                      |                     |
| 6. M                  | AKE A          | FINAL TB DI                           | AGNOSI              | S, CLASS                                | IFY TB D                 | ISFASE &   | SEICO                      |  |            |                             | <del></del>        | 1218        | 11.  |                      | ·                   |
|                       |                |                                       | Unc                 | omplica                                 | ted TB                   | Co   | mplicate                   | TB#  | NI REGI    | MEN <i>(CII</i><br>sseminat | CLE & T            | TCK APPL    |  |                      |                     |
| ∐Man                  | v+xııot<br>MA  | e/TB contact<br>D                     | □ртв                | (adenopat                               | һу опіу)                 | □Exter   | nsive PTB/Si               |  |            | eminated (                  |                    | , I         |  | sistani              |                     |
| □Unde                 |                |                                       | ☐ bleau<br>☐ □ Leub | neral IB a<br>al <del>ell</del> osion   | denopathy<br>(unilateral |  | ıminal TB<br>3-articular/9 | - 1 <del></del> 1                                | Птви       | eningitis                   |                    |             | ionore<br>IDR (R   | esistanci<br>& H res | :<br>istance)       |
| □HīVir                |                |                                       |                     |   |                          | □Perio   | ardial TB                  |  |            |                             |                    |             | DR   |                      | •                   |
| TB sy                 | HTTW<br>statom | OUT<br>Is or signs                    |                     |   |                          | ion  |                            |  |            | M                           | IDR/X              | DR tean     | MUST   |                      |                     |
| Drug                  | Dose<br>(mg/k  | 2 Duration                            | Drug                | Dose                                    | Duration                 | □ Retre  | Doze                       | Doctor   | <u> </u>   | Dosa                        | I ==               |             | devis  | e CARE               | PLAN                |
| INH                   | 10-1           |                                       | HIAI                | (rag/kg)<br>10-15                       | (montis)<br>6            | <del>                                     </del> | (mg/kg)                    | (months)   | Drug       | (mg/kg)                     | Duratio<br>(months | . n         | g   {  | Dosa .<br>ing/kg)    | Duratio<br>(raontie |
|                       |                |                                       | Rif                 | 10-20                                   | - 6                      | INH<br>Rif                                       | 10-15                      |  | INH        | 20                          | 6                  |             |  |                      | g-situa             |
|                       |                |                                       | PZA                 | 30-40                                   | 2                        | PZA  | 30-40                      | 6<br>2   | Rif<br>PZA | 20                          | 6                  |             |  |                      |                     |
| *4.dd D1              |                |                                       |                     |   |                          | Etham  | 15-25                      | 2  | Ethio      | 40<br>15-25                 | 6<br>5             |             |  |                      |                     |
|                       |                | 25 mg daily x 6                       |                     |   |                          |  |                            |  |            |                             |                    |             |  |                      |                     |
| 7. MA                 | KE A           | B TREATME                             | NT PLAN             | I (USETH                                | E ABOVE C                | LASSTFICA:                                       | πον το α                   | DIMPLETE I                                       | EO⊋ Tuic   | למווה)                      |                    |             |  |                      | -                   |
| *Tabl                 | et             | Drug                                  |                     | Соптроз                                 | ttion(mg)                | No. tabs   | Duration                   | Treatme  | ent start  | Planner                     | l end              | 1. 50       |  | <del></del>          |                     |
| . н                   | [              | lsoniazi                              | -                   | 15                                      | DG .                     |  | (m)                        | Cita   | 色          | dat                         | 2                  | luitiatio   | n site   | Follo                | w up site           |
| RHZ                   |                | Rifampicin / Is<br>Pyrazinan          |                     |   | 0/150                    |  |                            | 1  |            | -                           |                    |             |  | <del> </del>         |                     |
| RH (eire<br>applicabl |                | Rifampicin / Is                       |                     | 50/60 or<br>300/                        | 150/75 or<br>150         |  | <u> </u>                   |  | ·          |                             |                    |             |  | <del> </del>         | ·                   |
| RHZE                  |                | Rlfampicin / Isc<br>Pyrazīnamide / Et | hannbuto)           | 150/75/                                 | £00/275                  |  |                            | <del>                                     </del> |            | ·····                       |                    |             |  | <u> </u>             |                     |
| thio OR E             | tham           | Ethionamide / Et                      | <del></del>         | 40                                      | 0                        |  |                            |  |            |                             |                    |             |  |                      |                     |
| Z<br>maximura         | đaily đ        | Pyrednem<br>ose: H-300mar I           | de<br>2 Different   | 150 e                                   | 500                      |  |                            |  |            | <del></del>                 | $\neg +$           |             |  |                      | <del>"</del>        |
| hildren <4.           | <u>ka)</u>     | ase: H-300mg; )                       | , ial mithe         | -41 (OUVII) <u>G</u>                    | u; z-ryraza              | iamide (20                                       | 00mg); Ethi                | o-Ethionar                                       | nide (100  | Orng); E/Eti                | iom-Etho           | mbutol (    | 1375m  | g, not u             | sed in              |
| . CHEC                | CK HII         | TREATMEN                              | T PLAN              |   |                          |  |                            |  |            |                             |                    |             |  |                      |                     |
| ] HIV inf             | ected          | If not on ART                         | start ART           | 2 weeks a                               | iter TB tree             | mentstarti                                       | ed. Apr                    | start date                                       |            | <u></u>                     |                    | <del></del> | -  |                      |                     |
| Fau                   |                | REMEMBERT                             |                     |   |                          |  | 1                          |  |            |                             |                    |             | V unii   | uected               | I                   |
| . Foll                | Speci          | P SAMPLES (I                          | 00 AT 2             | /12 IF P                                | RE-TREA                  | IMENT S  | AMPLES 1                   | VE, OR I   | F СЦИЮ     | AL DETE                     | RIORAT             | ion)        | · · · · · · · · · · · · · · · · · · ·  |                      |                     |
|                       |                | putum / IS                            | +-                  | Date                                    |                          | Lab ID   |                            | 3-PCR  |            | оѕсору                      | 1                  | diure       | 1  | Sensit               | vitv                |
|                       |                | putum / IS                            | _                   |   |                          |  |                            | <del></del>                                      | <u> </u>   |                             |                    |             |  |                      |                     |
| 3 <sup>n</sup>        | d GW /         | Sputum                                |                     | * · · · · · · · · · · · · · · · · · · · |                          |  |                            |  | <u> </u>   | ·                           | <u> </u>           |             | $oldsymbol{ol}}}}}}}}}}}}}}}}}}$ |                      |                     |
| O. CHEC               | K RESI         | ONSE TO TR                            | FATRICA             | Jr praki                                | 07 FOLL                  |  |                            | <del></del>                                      | <u> </u>   |                             |                    |             |  |                      |                     |
|                       |                |                                       | - CATACLE           | AL PLANE.                               | AI FULL                  | NV UP  | 11-                        |  |            |                             |                    |             |  |                      | _                   |
|                       |                |                                       |                     |   | F                        | b qu-wollo                                       |                            | onth   | 2 month    | ıs 4 m                      | onths              | र १९२० ह    | tins   | E                    | nd                  |
|                       |                | nce good (Chec                        |                     |   |                          | (v)  | (n)                        |  |            |                             |                    |             |  | <u> </u>             |                     |
| nical: Gro            | wing w         | ell and, remains                      | well or             | symptoms                                | /signs imp               | roved (y/  | n)                         | ~_ <del> </del>                                  |            |                             |                    |             |  |                      |                     |
|                       |                | , has there bee                       |                     |   |                          | (y/n/na,   |                            |  |            |                             |                    | <u> </u>    |  | <del></del>          |                     |
|                       |                | 1 paediatricia                        |                     | _                                       | above is 'i              | Vo') (у/п  | )  -                       |  |            |                             |                    |             |  | <del> </del> -       |                     |
| SOURC                 | E CASE         | DETAILS (CI                           | RCLE APP            | LICABLE)                                |                          |  |                            |  |            |                             |                    |             |  |                      |                     |
| Nan                   | na 2 50        | hura es es es                         |                     |   | Prim                     | ary care   | jiver                      |  |            |                             | Other s            | ource c     | ase  |                      |                     |
|                       |                | ture of relation<br>toms getting be   | 1                   |   |                          |  |                            |  |            |                             |                    |             |  |                      |                     |
|                       |                | re result of con                      |                     | Sensit                                  |                          | Y/ N / ?   | /3.45= *:                  |  |            |                             |                    | N /?        |  |                      |                     |
|                       |                |                                       |                     | <u> </u>                                | INDONA (S                | esistence ,                                      | /MDR/XD                    | R / 7  | 9          | ensitive / I                | <i>V</i> ionoresi  | stence /    | MDR/   | XDR/                 | ?                   |


## Weight-for-Height Reference Card (87 cm and above)

|              | 700                | Height |               | Gii    | ıls' weight ( | kg)          |              |        |         |        |
|--------------|--------------------|--------|---------------|--------|---------------|--------------|--------------|--------|---------|--------|
| -4 SD        | -3 SD              | -2 SD  | -1 SD         | Médian | (cm)          | Médian       | -1 SD        | -2 SD  | -3 SD   | -4SD   |
| 8.9          | 9.6                | 10.4   | 11.2          | 12.2   | 87            | 11.9         | 10.9         | 10.0   | 9.2     | 8.4    |
| 9.1          | 9,8                | 10.6   | 11.5          | 12.4   | 88            | 12.1         | 11.1         | 10.2   | 9.4     | 8.6    |
| 9.3          | 10.0               | 10.8   | 11.7          | 12.6   | 89            | 12.4         | 11.4         | 10,4   | 9.6     | 8.8    |
| <b>9.</b> ₹. | 10.2               | 11.0   | 11.9          | 12.9   | 90            | 12.6         | 11.6         | 10.6   | 9.8     | 9.Qʻ   |
| 9.6          | 10.4               | 11.2   | 12.1          | 13.1   | 91            | 12.9         | 11.8         | 10.9   | 10.0    | 9.1    |
| · 9,8        | 10.6               | . 11.4 | 12.3          | 13.4   | 92            | 13.1         | 12.0         | 11.1.  | 10,2    | 9.3    |
| 9,9          | 10.8               | 11.6   | 12.6          | 13.6   | 93            | 13.4         | 12.3         | 11.3   | 10.4    | 9.5    |
| 10.1         | 11.0               | 11.8   | 12.8          | 13.8   | 94            | 13.6         | 12.5         | 11.5   | 10.Ĝ    | 9.7    |
| 10.3         | 11.1               | 12.0   | 13,0          | 14.1   | 95            | 13.9         | 12.7         | 11.7   | 10.8    | 9,8 .  |
| 10. <b>4</b> | 11.3               | 12.2   | 13.2          | 14.3   | . 96          | 14.1         | 12,9         | 11.9   | 10.9    |        |
| 10.6         | 11.5               | 12.4   | 13.4          | 14.6   | . 97          | 14.4         | 13.2         | 12.1   | 11.1    | 10.2   |
| 10.8         | 11.7               | 12.6   | 13,7          | 14.8   | 38 .          | 14.7         | 13.4         | 12.3   | 11.3    | 10.4   |
| 11.0         | 11.9               | 12.9   | .13.9         | 15.1   | 99            | 14.9         | 13.7         | 12.5   | 11.5    | 10.5   |
| 11.2         | 12.1               | . 13.1 | 14.2          | 15.4   | 100           | 15.2         | 13.9         | 12.8   | 11.7    | 10.7   |
| 11.3         | 12.3               | 13.3   | 14.4          | 15.6   | 101           | 15.5         | 14.2         | 13.0   | 12.0    | 10.9   |
| 11.5         | 12.5               | 13.6   | 1 <i>4.</i> 7 | 15.9   | 102           | 15.8         | 14.5         | 13.3   | 12.2    | 11.1   |
| 11.7         | 12.8               | 13.8   | 14.9          | 16.2   | 103           | 16.1         | 14.7         | 13,5   | 12,4    | 11.3   |
| 11.9         | 13.0               | 14.0   | 15.2          | 16.5   | 104           | 16.4         | 15.0         | 13.8   | 12.6    | 11.5   |
| 12.1         | 13.2               | 14.3   | 15.6          | 16.8   | 105           | 16.8         | 15.3         | 14.0   | 12.9    | 11.8   |
| · 12.3       | 13,4               | 14.5   | 15.8          | 17.2   | 106           | 17.1         | 15.6         | 14.3   | 13.1    | 12.0   |
| 12.5         | 13.7               | 14.8   | 16.1          | 17.5   | 107           | 17.5         | 15.9         | 14.6   | 13.4    | 12.2   |
| 12.7         | ·13.9              | 15.1   | 16.4          | 17.8   | 108           | 17.8         | 1 <b>6.3</b> | 14.9   | . 13.7  | 12.4   |
| 12.9         | 14.1               | 15.3   | 16.7          | 18.2   | 109           | 18.2         | 16.6         | 15.2   | 13.9    | 12.7   |
| . 13.2       | , 14. <del>4</del> | 15.6   | 17.0          | . 18.5 | - 110         | 18.6         | 17.0         | 15,Ś   | 14.2    | 12.9 . |
| 13.4         | 14.6               | 15.9   | 17.3          | 18.9   | 111           | 19.0         | 17.3         | 15.8   | 14.5    | 13.2   |
| 13.6         | 14.9               | 16.2   | 17.6          | 19.2   | 112           | 19.4         | .17.7        | 16.2   | 14.8    | 13.5   |
| 13.8         | 15.2               | 16.5   | 18.0          | 19.6   | 113           | 19.8         | 18.0         | 16.5   | 15,1    | 13.7   |
| 14.1         | 15.4               | 16.8   | 18.3          | 20.0   | 11 <b>4</b>   | 20.2 `       | 18.4         | 16.8   | 15,4.   | -14.0  |
| 14.3         | 15.7               | 17.1   | 18.6          | 20.4   | 115           | 20 <i>.T</i> | 18.8         | . 17.2 | . 15.7- | 14.3   |
| 14.6         | 16.0               | 17.4   | 19.0          | 20.8   | 116 .         |              | 19.2         | 17.5   | 16.0    | 14.5   |
| 14.8         | 15.2               | 17.7   | 19,3          | 21.2   | 117           | 21.5         | 19.6         | 17,8   | 16.3    | 14.8   |
| . 15.01      | 16.5               |        | 19.7          | 21.6   | 118           | 22.0         | 19.9         | 18.2   | 16.6    | 15.1   |
| 15,3         | 16.8               | 18.3   | 20.0          | 22.0   | 119           | 22.4         | 20,3         | 18.5   | 16.9    | 15.4   |
| 15.5         | 17.1               | 18.6   | 20.4          | 22.4   | 120           | 22.8         | 20.7         | 18.9   | 17.3.   | 15.6   |

## Weight-for-Length Reference Card (below 87 cm)

|     | Boys' weight (kg) |       |               |             |              |                   |         | Girls' weight (kg) |                 |                 |                    |
|-----|-------------------|-------|---------------|-------------|--------------|-------------------|---------|--------------------|-----------------|-----------------|--------------------|
|     | -4 SD             | -3 SD | -2 SD         | -1 SD       | Médian       | (cm)              | Médian  | -1 SD              | -2 SD           | -3 SD           | -4 SD              |
|     | 1.7               | 1.9   | 2.0           | 2.2         | 2.4          | 45                | 2.5     | 2,3                | 2,1             | 1,9             | 1.7                |
|     | 1.8               | 2.0   | 2.2           | 2.4         | 2,6.         | 46                | 2.6     | 2,4.               | 2.2             | 2.0             | 1.9                |
|     | 2.0               | 2.1   | 2.3           | 2.5         | 2.8          | <b>47</b>         | 2.8     | 2.6                | 2.4             | 2.2             | 2.0                |
| ٠   | 2.1               | 2.3   | 2.5           | 2.7         | 2.9          | 48                | 3.0     | 2,7                | <b>2.</b> 5     | -2.3 .          | 2,1                |
|     | 2.2               | 2.4   | 2.6           | 2.9         | 3.1          | 49                | 3,2     | 2.9                | 2.5             | 2.4             | 2.2                |
|     | 2.4".             | 2,6   | 2.8           | <b>3.</b> 0 | 3.3          | . <b>50</b> ·     | 3.4     | 3.1                | 2.8             | 2.6             | 2.4                |
|     | 2.5               | 2.7   | 3.0           | 3,2         | -3.5         | 51                | 3.6     | 3.3                | 3.0             | 2.8             | 2.5                |
|     | 2.7               | 2.9   | 3.2           | 3,5         | 3,8          | 52                | 3.8     | 3,5                | 3.2             | 2.9             | 2.7                |
|     | 2.9               | 3.1   | 3,4           | 3,7         | 4.0          | 53                | 4.0     | 3.7                | 3.4             | 3.1             | 2.8                |
|     | 3.1               | 3.3   | 3.5           | . 3,9       | 4.3          | 54                | 4,3     | ·3,9 ·             | 3.6             | 3.3             | 3.0                |
|     | 3.3               | 3.8   | 3.8           | 4.2         | 4.5          | 55                | 4.5     | 4.2                | 3,8             | 3,5             | 3.2                |
|     | 3.5               | . 3,8 | 4.1           | 4.4         | 4,8          | 56                | 4.8     | 44.                | 4.0             |                 | 3.4                |
|     | 3.7               | 4.0   | 4.3           | 4.7         | 5.1          | 57                | 5.1     | 4.6                | 4.3             | 3,9             | 3,6                |
| ٠   | 3.9               | 4.3   | . <b>₹</b> .6 | 5.0         | 5.4          | 58                | 5.4     | 4.9                | 4.5             | · 4.1           | 3.8                |
|     | 4.7               | 4.5   | 4.8           | 5.3         | 5.7          | <del>59</del>     | 5,6     | 5.1                | 4.7             | 4.3             | 3,9                |
|     | 4.3               | · 4.7 | - 5.1         | 5,5         | 6.0          | ĠQ į              | . 5.9   | 5.4                |                 | 4.5 .           | 4,1                |
|     | 4.5               | 4,9   | 5.3           | 5.8         | 6,3          | 61                | 6.1     | 5.6                | 5.i             | 4.7             | 4.3                |
| •   | 4.7               | 5.1   | 5.6           | 6.0         | 6,5          | 62                | 6.4     | 5,8                | 5.3             | 4.9.            | 4.5                |
|     | 4.9               | 5.3   | _ 5,8         | 6.2         | 6.8          | 63                | 5.6     | 6.0                | 5.5             | 5.1             | 4.7                |
|     | 5.1               | 5.5   | , 6,0         | 6.5         | 7.0          | 64                | . 6,9   | 6.3:               | 5.7             | 5.3             | 4.8                |
|     | 5.3               | 5.J · | 6.2           | ទ.7         | 7.3          | 65                | 7.1     | 6.5                | 5. <del>9</del> | 5.5             | 5.0                |
| • • | <b>5.</b> 2       | · 5.9 | €'₹           | 6.9 ·       | 7.5          | 56 :              | 7.3     | 6.7                | 6.1             | 5.5             | δ <sub>≈</sub> 1;  |
|     | 5.6               | 6.1   | 6,6           | 7.1         | . 7.7        | 67                | 7.5     | 6,9                | 6.3             | 5.8             | 5.3                |
|     | 5,8               | 6.3   | 6.8           | 7.3         | . B.O ·      | 68                | 7.7 F   | 7.1                | 6.5             | . 6:9           | . <b>5</b> .5      |
|     | 6.0               | 6.5   | 7.0           | 7.6         | 8.2          | 69                | 0.8     | 7,3                | 6.7             | 6.1             | 5,6                |
|     | ∂.1               | 6.6   | 7.2           | 7.8         | <b>\$,</b> 4 | 70.               | · 8,2 . | 7.5                | 6.9. ·          |                 | 5.8                |
|     | 6.3               | 8.8   | 7.4           | 8.0         | 8,6          | 71                | 8.4     | 7.7                | 7.0             | 6.5             | 5.9                |
| •   | 6.4               | 7.0   | 7.6           | 8.2         | 8,9          | 72                | . 8.6   | 7.8                | 7.2             | 6.6             | 6.0                |
|     | 6.6               | 7.2   | 7.7           | 8.4         | 9.1          | 73                | 8.8     |                    | 7.4             | 6. <del>8</del> | 6.2                |
|     | 6.7               | 7.3   | 7.9           | 8.6         | <b>5</b> '3  | 74                | 9.0     | 8.2                | .7.5            | 6.9             | · 6,3              |
|     | 6.9               | 7.5   | 8.1           | 8.8         | 9,5          | 75                | 9.1     | 8,4                |                 | 7.1             | 6.5                |
|     | 7.0               |       | · 8*3         | . 8,9       | . 9.7        | . 76.             | £3 ·    | 8.5                | 7.8             | 7.2             | 6,6                |
| •   | 7.2               | 7.8   | 8.4           | 9.1         | 9,9          | 77                | 9.5     | 8.7                | 8.0             | 7.4             | 6.7                |
|     | 7.3               |       | 8,5           | 9.3.        |              | 7 <del>8</del> 5. | 9.7     | 8.9                | 8.2             | . 7 <b>.</b> 5  | 6 <b>.</b> 8       |
| •   | 7.4               | 8.1   | 8.7           | 9.5         | 10.3         | 79                | 9,9     | 9.1                | 8.3             | 7.7             | 7.0                |
|     | 7.6               | 8.2   | 8,9           | . 9.6       | 10,4         | 80                |         | 9,2                | 8,5             | 7.8             | 7.3                |
| •   | 7.7               | 8.4   | 9.1           | . 9.8       | 10.6         | 81 •              |         | 9.4                | . 8.7.          | 8.0             | 7.3.               |
|     | 7.9               | 8.5   | 9.2           | 10.0        | 10,8         | 82                | 10.5    | 9.6                | 8.8             | . 8.1           | 7.5                |
|     | 8.0               | 8.7   | 9.4           | 10.2        | 11.0         | 83                | 10.7    | 9.8                | 9.0             | 8.3             | 7.6                |
|     | 8:2               | 8.9   | 9.6           | 10_4        | 11,3         | 84                | _11.0   | 10.1               | .: 9.2.         | 8.5             | 7 <del>.</del> 8 · |
|     | 8.4               | 9.1   | 9,8           | 10.6        | 11.5         | 85                | 11.2    |                    | 9.4             | 8.7             | 8.0                |
|     | 8.6               | 5.3   | 10.0          | 10.8        | 11.7         | 86                | 11.5    | 10.5               | 9.7             | 8,8             | 8.1                |







## (F)

## Weight-for-age BOYS

5 to 10 years (z-scores)






2007 WHO Reference

## Height-for-age BOYS

5 to 19 years (z-scores)






2007 WHO Reference

# BMI-for-age BOYS 5 to 19 years (z-scores)






2007 WHO Reference


# BMI-for-age GIRLS 5 to 19 years (z-scores)






2007 WHO Reference


| Name:  |            |
|--------|------------|
| ranno. | Folder No: |





## Weight-for-age GIRLS 5 to 10 years (z-scores)






2007 WHO Reference


## Height-for-age GIRLS





# Weight-for-age BOYS 5 to 10 years (z-scores)






2007 WHO Reference

## Height-for-age BOYS

5 to 19 years (z-scores)









| Name:                                 |              |                                       |          |  |  |           | Folde  | er No:   |              |          |  |          |
|---------------------------------------|--------------|---------------------------------------|----------|--|--|-----------|--|----------|--------------|----------|--|----------|
| Investigations                        |              |                                       |          | -  |  |           |  |          |              |          |  | _        |
| Chemistry & Haer                      | matolog      | 3Y                                    |          |  |  |           |  | -        |              |          |  | -        |
| Date                                  |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Time                                  |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Renal Function                        |              |                                       | ·        |  |  |           |  |          |              |          |  |          |
| Sodium                                |              |                                       | "        |  |  |           |  |          |              |          |  |          |
| Potassium                             |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Chloride                              |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Bicarbonate                           |              |                                       |          |  | •  |           |  |          |              |          |  |          |
| Urea                                  |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Creatinine                            |              |                                       |          |  |  |           |  |          |              |          |  |          |
|                                       |              |                                       |          |  | -  |           |  |          |              |          |  |          |
|                                       |              |                                       |          |  |  |           |  | ,        |              |          |  |          |
| "CMP"                                 |              |                                       | · - ·    |  | ·  | <u></u> j | l  |          | •            |          |  | -        |
| Ca <sup>2+</sup> /Corrected           |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Magnesium                             |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Phosphate                             |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Liver Function                        |              |                                       |          |  |  |           |  |          |              |          | 1  |          |
| Total Protein                         |              |                                       |          |  |  |           |  |          |              |          |  | •        |
| Albumin                               |              |                                       | -        |  |  |           |  |          |              |          |  |          |
| Total bili / Conj bili                |              |                                       |          |  |  |           |  |          |              |          |  |          |
| ALT/AST                               |              |                                       |          |  |  |           |  |          |              |          |  |          |
| ALP                                   |              |                                       |          |  |  |           |  |          |              |          |  |          |
| GGT                                   |              |                                       |          |  |  |           |  |          |              |          |  |          |
| LDH                                   |              | <u></u>                               |          |  |  |           |  |          |              |          |  |          |
| INR                                   |              |                                       |          |  |  |           |  |          |              |          |  |          |
| Haematology                           |              | <u> </u>                              | <u></u>  | <u> </u>   | <u></u>  |           |  |          |              |          | <u>.                                    </u> | l        |
| wcc                                   | <u> </u>     |                                       |          |  |  |           |  |          |              |          |  |          |
| N%                                    |              |                                       |          |  |  |           |  |          |              |          | ·  |          |
| 1%                                    |              |                                       | <u> </u> | <u> </u>   | **   |           |  |          |              |          |  |          |
| Hb                                    |              |                                       | ļ        | <b> </b>   |  |           |  |          |              |          |  |          |
| MCV                                   |              |                                       |          |  |  |           |  |          |              |          |  | 1        |
| Platelets                             |              |                                       |          |  |  |           |  |          |              | ļ        |  |          |
| Retics                                |              |                                       |          | <del>                                     </del> |  |           | ·  | -=       |              | <b> </b> |  | 1        |
| ESR/CRP                               | ļ            |                                       |          | <del>                                     </del> |  |           |  |          |              |          |  |          |
| Acid/Base & Bloc                      | <u> </u>     | es                                    |          | <u> </u>   |  |           |  | <u> </u> |              |          |  | 1        |
| Date                                  |              |                                       | T        |  |  |           |  | 1        |              |          |  | ].       |
| Time                                  |              |                                       |          |  |  |           |  |          |              |          |  | <u> </u> |
| A (Art) or V (Ven) / FiO <sub>2</sub> |              |                                       |          |  | 1  |           |  |          |              |          |  | 1        |
| pH                                    | <u> </u>     | · ·                                   |          |  |  |           |  |          | <u> </u>     |          |  | +-       |
| pCO <sub>2</sub>                      | <del> </del> | · · · · · · · · · · · · · · · · · · · |          |  |  |           | <del>                                     </del> |          | <u> </u>     |          | <b></b>                                      | 1        |
| pO <sub>2</sub>                       | +            | -                                     | -        |  |  |           |  |          | <del> </del> |          |  | 1        |
| SBC / Base Excess                     |              | +                                     | + -      | +-   | +  | + ->      | <del>                                     </del> |          | +            | +        | +  | 1        |
|                                       | f            |                                       |          |  | <del>                                     </del> |           |  |          |              |          | +  | 1        |
| Lactate                               | 1            | 1                                     | Į.       | l .  | 1  | 1         | 1  | 1        | ı            | 1        | 1  | 1        |

| Name:                                 |   | Folder No: |
|---------------------------------------|---|------------|
| Cultures                              | <u>-</u>                                |            |
| Date                                  | Test                                    | Result     |
|                                       |   |            |
|                                       |   |            |
|                                       |   |            |
|                                       |   |            |
|                                       |   | -          |
|                                       |   |            |
|                                       |   |            |
|                                       |   |            |
| Serology                              | Mark and the                            |            |
| . Date                                | Test                                    | Result     |
|                                       |   |            |
|                                       |   |            |
| · · · · · · · · · · · · · · · · · · · |   |            |
|                                       |   |            |
|                                       |   |            |
|                                       |   | ·          |
| Radiology                             |   |            |
| Date                                  | Image                                   |            |
|                                       |   | ·          |
|                                       |   |            |
|                                       |   |            |
|                                       |   | -          |
|                                       |   |            |
|                                       |   |            |
|                                       |   |            |
| Other/Special                         | <u> </u>                                |            |
| Date                                  | Test                                    | Result     |
|                                       |   |            |
|                                       | *************************************** |            |
| ,                                     | ,                                       |            |
| · · · · · · · · · · · · · · · · · · · |   |            |

|   | (igama jomntwana) ngitsheliwe   | Yes No   |  |
|---|---|--|--|
| Department of Paediatrics – Edendale Hospital<br>Patient Counselling Form |   | o) Yes No Yes No   |  |
|   | March Department:  Ward  Ward  Health  PROVINCE OF KWAZULLI-NATAL  IP Number: | Mina, (Igama) (ubuhlobo) ngokulandelayo mayelane nomtwana yes No |  |

| Patient Counselling Form  Patient Counselling Form  Patient Counselling Form  Patient Counselling Form  (Journaling Form)  (Journaling Form  (Journaling Form)  (Journaling Form) |  |
|--|--|
|--|--|



### Clinical Notes

| lame: | *************************************** |   | Ward:    |          |
|-------|---|---|----------|----------|
| Date  | Time                                    | History, clinical findings and progress notes |          | Sign     |
|       |   | W7=   |          | <u> </u> |
|       |   |   |          |          |
| •     |   | ·   |          |          |
|       |   |   |          |          |
|       |   | -   |          |          |
|       |   |   | •        |          |
|       |   |   |          |          |
|       |   |   |          |          |
| ····  |   |   |          |          |
|       |   |   |          |          |
|       |   |   | <u> </u> |          |
|       |   |   | •        |          |
|       |   | . • •   |          |          |
|       |   |   | *        |          |
|       |   |   |          |          |
| •     |   |   |          |          |
|       |   |   |          |          |
| ,     |   |   |          |          |
|       |   |   |          |          |
|       |   |   |          |          |
|       |   |   | •        |          |
|       |   |   |          |          |
|       |   | ·   |          |          |
|       |   | ·   |          |          |
|       |   |   | ·        |          |
|       |   |   |          |          |
|       |   |   |          |          |

|      | т    | History, clinical findings and progress notes |   | Sign         |
|------|------|---|---|--------------|
| Date | Time | . Pistoly, circus many                        |   |              |
|      |      |   |   |              |
|      |      | ,   |   |              |
|      |      | ·   |   |              |
|      |      |   |   |              |
|      | -    |   |   |              |
|      |      |   |   | •            |
|      |      |   |   |              |
|      | _    |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      | ·   |   | •            |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   | :            |
|      | ·    |   |   | ·<br>        |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   | -            |
|      | 34   |   |   |              |
|      |      |   |   | <u> </u>     |
|      |      |   |   | <del> </del> |
|      |      |   |   |              |
|      |      |   |   | <u> </u>     |
|      |      |   |   |              |
|      |      |   | • | ,            |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |
|      |      |   |   |              |